Castleark Management’s Heron Therapeutics HRTX Stock Holding History

Castleark Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-87,660	Closed	-$2.77M	–	384
2018 Q3	$2.77M	Sell	87,660 -113,420	-56%	-$4.22M	0.08%	227
2018 Q2	$7.81M	Buy	201,080 +141,505	+238%	+$4.5M	0.24%	134
2018 Q1	$1.64M	Buy	+59,575	New	+$1.35M	0.05%	260

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Castleark Management's HRTX Position: Q4 2018 in Review

Castleark Management sold out of Heron Therapeutics (HRTX) in Q4 2018, closing a stake of 87,660 shares — an estimated $2.77M sold.

Castleark Management first reported a position in HRTX in Q1 2018 and held it in 3 quarters. The position peaked at $7.81M in Q2 2018. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2018.

Castleark Management reported no remaining Heron Therapeutics position as of Q4 2018 after selling out during the quarter.
Castleark Management sold 87,660 Heron Therapeutics shares in Q4 2018, an estimated $2.77M.
Castleark Management first reported a position in Heron Therapeutics in Q1 2018 and held it in 3 quarters.
Castleark Management's Heron Therapeutics position peaked at $7.81M in Q2 2018.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2018.

Based on Castleark Management's 13F filing for Q4 2018, filed 12 Feb 2019.